OUR PEOPLE: Innovation Board

The Innovation Board brings together the industrial and academic partners of the Consortium to determine the overarching challenges facing the pharmaceutical industry and predict future needs. It enables companies to collaborate on common research projects related to targets, technologies and therapeutic areas. The Consortium companies are in a position to fund collectively major projects of common interest. Its remit is to consider the future direction of therapeutic research and suggest innovative projects for collective company funding. Research projects selected by the Innovation Board are executed by a ‘task force’ of academic and company groups with appropriate expertise.

Dr John Lyons

Dr John Lyons

Astex
Senior Vice President of Translational Research

Dr Susan Galbraith

AstraZeneca
Vice President, Head of Oncology iMed, Innovative Medicines

Dr Alexa Smith

AstraZeneca
Senior Director
External R&D and Strategic Alliances

Dr Sue Bailey

Bristol Myers Squibb
Strategic Partnership and Early Asset Director, UK&Ireland

Dr Peter Atkinson

Eisai
Director & Head of Open Innovation,
Neurology Business Group

Dr Andy Takle

Eisai
Executive Director & Head of Hatfield Research Laboratories,
Neurology Business Group

Dr Natalia Novac

Eli Lilly & Company
Senior Director Emerging Technologies and Innovation
Corporate Business Development

Dr Hugh Nuthall

Eli Lilly & Company
Senior Director
Search & Evaluation Neuroscience

Mark Morris

Dr Joerg Hoeck

Ferring
Associate Director, External Innovation & Scientific Licensing

Mark Morris

Dr Declan Jones

Ferring
Vice President, Head of External Innovation & Scientific Licensing 

Dr Rab Prinjha

Dr Rab Prinjha

GlaxoSmithKline
Vice President, Head of Epigenetics Drug Performance Unit (DPU)

Dr Richard Mason

Dr Lilian Alcaraz

Johnson & Johnson
Senior Director, New Ventures & Transactions, Neuroscience

Mark Morris

Dr Ann Connolly

Johnson & Johnson
Senior Director, New Ventures & Transactions, Infectious Disease and Vaccines

Mark Morris

Dr David Shields

Pfizer
Vice President and Head
Centers for Therapeutic Innovation East

Dr Kai Stoeber

Dr Ryuichi Kiyama

Shionogi
SVP, Head of Pharmaceutical Research Division

Dr Kai Stoeber

Dr Yoshiro Shiba

Shionogi
Global Innovation and Alliance Manager

Dr Simon Cook

Dr Simon Cook

Babraham Institute
Group Leader, Signalling Programme

Prof Greg Hannon

CRUK Cambridge Institute
Royal Society Research Professor

 

Dr Mathew Garnett

Dr Mathew Garnett

Sanger Institute
Group Leader, Translational Cancer Genomics

Ludovic Vallier

Prof Ludovic Vallier

University of Cambridge
Senior Group Leader, Wellcome MRC Cambridge Stem Cell Institute
Prof Tony Kouzarides

Prof Tony Kouzarides

Milner Therapeutics Institute
Director

Dr Kathryn Chapman

Milner Therapeutics Institute
Deputy Director

In memory of Professors Michael Wakelam and Chris Abell. Milner Innovation Board members, and friends, who are sadly no longer with us.

Professor Michael Wakelam

Prof Michael Wakelam

Board Member
2015-2020

Michael will be remembered by the Milner for his invariably positive presence. He always reassured and motivated us when things were hard, keeping our spirits up and giving us the guidance we needed to progress. He was generous with his time and offered the use of anything at his disposal that would help towards the Milner vision. It is because of Michael that the Milner has such a fruitful, rewarding relationship with the Babraham Institute and campus. He understood the barriers and drivers for working with industry and had a passion equal to the Milner’s for cultural change and increased interactions between industry and academia. Above all, he was always warm and smiling. He always made us feel good about what we were doing and why we were doing it. He is sorely missed by all of us at the Milner. Michael was a member of the Milner Innovation Board from 2015-2020.

https://www.babraham.ac.uk/news/2020/04/memories-michael-colleagues-tribute

Prof Chris Abell

Prof Chris Abell

Board Member
2015-2020

Chris will be remembered for his phenomenal impact on science, entrepreneurship and drug discovery in Cambridge. He will also be remembered personally by all who had the privilege of working with him. We all have our own stories and memories, many of which can be found on Chris’s memorial page here – https://www.remembr.com/en/professor.chris.abell. This memorial is to show our appreciation of Chris’s support of the Milner Therapeutics Institute. Chris was always supportive of the Milner from its inception. He was a proactive and incisive member of the Milner Governance Board from 2015 to 2020, challenging our ideas and providing insightful wisdom from his wealth of expertise. Most importantly, he gave us the space and freedom to experiment and test our new model of collaboration. He had an inherent understanding of research and innovation and balanced that with ongoing fervent support for entrepreneurship and translational research. Chris was instrumental in helping the Milner to find its feet within the University and the Cambridge cluster and we will always be grateful for his encouragement and support.

Pin It on Pinterest